Table 1.
The Clinical Characteristics of All the Patients
| No. of Patients | n=26 |
|---|---|
| Age (years) | |
| Median | 66.5 |
| IQR | 58.8–72.8 |
| Gleason score | |
| 6 | 9 |
| 7 | 5 |
| 8 | 8 |
| 9 | 4 |
| T staging | |
| T1 | 2 |
| T2 | 19 |
| T3 | 3 |
| T4 | 2 |
| Risk groups* | |
| Intermediate | 8 |
| High | 9 |
| Very high | 9 |
| Pre-treatment PSA value (ng/mL) | |
| Median | 7.09 |
| After treatment PSA value (ng/mL) | |
| Median | 1.65 |
Note: *These patients were classified into prognostic risk groups based on the National Comprehensive Cancer Network (NCCN) criteria.
Abbreviations: IQR, interquartile range; PSA, prostate specific antigen.